These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35361730)

  • 61. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
    Hamy AS; Pierga JY; Sabaila A; Laas E; Bonsang-Kitzis H; Laurent C; Vincent-Salomon A; Cottu P; Lerebours F; Rouzier R; Lae M; Reyal F
    Ann Oncol; 2017 Sep; 28(9):2233-2240. PubMed ID: 28911063
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
    Ladoire S; Arnould L; Apetoh L; Coudert B; Martin F; Chauffert B; Fumoleau P; Ghiringhelli F
    Clin Cancer Res; 2008 Apr; 14(8):2413-20. PubMed ID: 18413832
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
    Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.
    Lonie JM; Brosda S; Bonazzi VF; Aoude LG; Patel K; Brown I; Sharma S; Lampe G; Addala V; Koufariotis LT; Wood S; Waddell N; Dolcetti R; Barbour AP
    Front Immunol; 2023; 14():1220129. PubMed ID: 37965317
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Montfort A; Pearce OM; Topping J; Chakravarty P; Everitt GL; Clear A; McDermott JR; Ennis D; Dowe T; Fitzpatrick A; Brockbank EC; Lawrence AC; Jeyarajah A; Faruqi AZ; McNeish IA; Singh N; Lockley M; Balkwill FR
    Clin Cancer Res; 2016 Jun; 22(12):3025-36. PubMed ID: 27306793
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study.
    Cao G; Hua D; Li J; Zhang X; Zhang Z; Zhang B; Bei T; Cui L; Chen S; Wang S; Zhu L
    Front Immunol; 2023; 14():1022942. PubMed ID: 36993949
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
    Wattenberg MM; Colby S; Garrido-Laguna I; Xue Y; Chang R; Delman D; Lee J; Affolter K; Mulvihill SJ; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Sohal DPS; Beatty GL
    Gastroenterology; 2024 Jun; 166(6):1114-1129. PubMed ID: 38244727
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer.
    Gaui MFD; Amendola LC; Quintella DC; Canedo N; Bonomo A
    Rev Assoc Med Bras (1992); 2023; 69(9):e20230276. PubMed ID: 37729362
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.
    Jäntti T; Luhtala S; Mäenpää J; Staff S
    Tumour Biol; 2020 Nov; 42(11):1010428320971404. PubMed ID: 33169632
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
    Zhao Y; Li D; Zhuang J; Li Z; Xia Q; Li Z; Yu J; Wang J; Zhang Y; Li K; Xu S; Li S; Ma P; Cao Y; Liu C; Xu C; Liu Z; Wei J; Zhang C; Qiao L; Gao X; Hou Z; Liu C; Zheng R; Wang D; Liu Y
    Clin Transl Med; 2024 May; 14(5):e1674. PubMed ID: 38685486
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing.
    Jia F; Sun S; Li J; Wang W; Huang H; Hu X; Pan S; Chen W; Shen L; Yao Y; Zheng S; Chen H; Xia W; Yuan H; Zhou J; Yu X; Zhang T; Zhang B; Huang J; Ni C
    Cancer Lett; 2024 Mar; 585():216656. PubMed ID: 38266804
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment.
    Wang YL; Gong Y; Lv Z; Li L; Yuan Y
    J Cancer; 2021; 12(6):1698-1707. PubMed ID: 33613757
    [No Abstract]   [Full Text] [Related]  

  • 76. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8
    Tada Y; Togashi Y; Kotani D; Kuwata T; Sato E; Kawazoe A; Doi T; Wada H; Nishikawa H; Shitara K
    J Immunother Cancer; 2018 Oct; 6(1):106. PubMed ID: 30314524
    [TBL] [Abstract][Full Text] [Related]  

  • 77. ALDH1 and tumor infiltrating lymphocytes as predictors for neoadjuvant chemotherapy response in breast cancer.
    Lee A; Won KY; Lim SJ; Cho SY; Han SA; Park S; Song JY
    Pathol Res Pract; 2018 May; 214(5):619-624. PubMed ID: 29685462
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tumor-infiltrating CD226
    Zhang Y; Zhao ZX; Gao JP; Huang YK; Huang H
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4381-4389. PubMed ID: 36107244
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer.
    Lu J; Xu Y; Wu Y; Huang XY; Xie JW; Wang JB; Lin JX; Li P; Zheng CH; Huang AM; Huang CM
    BMC Cancer; 2019 Sep; 19(1):920. PubMed ID: 31521128
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.
    Abdul Sater H; Marté JL; Donahue RN; Walter-Rodriguez B; Heery CR; Steinberg SM; Cordes LM; Chun G; Karzai F; Bilusic M; Harmon SA; Turkbey IB; Choyke PL; Schlom J; Dahut WL; Madan RA; Pinto PA; Gulley JL
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32269146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.